PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano(University of Palermo), Alan Prem Kumar(National University of Singapore), Jennifer R. Brown(Dana-Farber Cancer Institute), Matthew H. Kulke(Moffitt Cancer Center), Camilla Pecoraro(University of Palermo), Hiu Yan Lam(National University of Singapore), Gautam Sethi(National University of Singapore), Jyothi S. Prabhu(St.John's Medical College Hospital), Daniela Carbone(University of Palermo), Pooyan Makvandi(Piaggio (Italy)), Birgit Geoerger(Inserm), Vincenzo Cavalieri, Patrizia Diana(University of Palermo), Nathalie Javidi‐Sharifi(Harvard University), Madhumathy G Nair(St.John's Medical College Hospital), William Jacot(Inserm), Robert H. Jones(Velindre NHS Trust), Matthew S. Davids(Dana-Farber Cancer Institute), Huiyan Eng(National University of Singapore), Daniel Boon Loong Teh(National University of Singapore), Kevin Lin(The University of Texas MD Anderson Cancer Center), Eneda Toska(Johns Hopkins University), Justin Stebbing(Anglia Ruskin University), Richard D. Baird(Cancer Research UK), Kenneth Chun-Yong Yap(National University of Singapore), Aaron Song Chuan Foo(National University of Singapore)
Cited by 1,928
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k